Pfizer Aktie News

Metsera stock surged Thursday on reports Pfizer has matched Novo Nordisk's $10 billion bid to buy the obesity-focused biotech.

A bidding war over U.S. biotech Metsera was coming to a head on Thursday, with Danish drugmaker Novo Nordisk locked in a $10 billion battle with U.S. rival Pfizer to win Metsera's obesity drug assets.

Pfizer offers a 7% dividend yield, providing steady income despite stagnant share performance in recent months. COVID-19 product sales have sharply declined, with Paxlovid down 55% and vaccine revenue falling 20% year-over-year. Pfizer is redirecting investment toward oncology and cardiometabolic markets, projected to exceed $70 billion by 2030.

FAA will reduce air traffic by 10% across 40 major markets due to staffing shortages from the government shutdown, impacting 3,500-4,000 flights daily. Pfizer (PFE) has matched Novo Nordisk's bid for obesity biotech Metsera (MTSR), valuing it at $10 billion, intensifying the takeover battle.

Pfizer's Q3 earnings fell, but the company still raised its full-year earnings guidance. Major cost reductions remain on track, which should significantly boost the drugmaker's bottom line.

Turnaround stocks often face a lot of negativity from investors until their turnaround efforts start bearing fruit. United Parcel Service is working to streamline its operations so it can become a more profitable business.

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today issued the following statement in response to the Delaware Chancery Court's decision denying Pfizer's request for a temporary restraining order to prevent Metsera, Inc. from terminating the existing merger agreement in favor of a competing proposal from Novo Nordisk. “We remain confident in the merits of our claims and our belief that Met...

Pfizer is preparing to sweeten its offer again for Metsera , the Wall Street Journal reported on Wednesday, citing people familiar with the matter.